N/A N=25 Observational Study of Ocular Inflammation in Patients Undergoing a Pars Plana Vitrectomy
Vitrectomy
Primary: Percentage of Participants With Vitreous Cell Count of 0 — 88.0 Percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=172 Efficacy and Safety of IBI-10090 in Ocular Surgery Patients
Inflammation Associated With Cataract Surgery
Primary: Anterior Chamber Cell Count at Day 8 Post-Treatment — 50; 51.8; 60.3 percentage of patients with ACC clearing
Phase 3 N=520 Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain
Post Surgical Ocular Inflammation and Pain
Primary: Complete Resolution of Anterior Chamber (AC) Cells at Day 8 — 54; 32 Participants — p=0.0105
Phase 3 N=219 Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002a)
Inflammation
Primary: Anterior Chamber Cell Grade of "0" on Day 8 (Difluprednate QID vs Placebo). — 0; 19; 13 participants — p=0.0014
Phase 2 N=109 RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery
Inflammation and Pain Following Ocular Surgery
Primary: Absence of Anterior Chamber Cells at Day 15 (Visit 5) — 10; 12; 11; 27 Participants — p=0.4543
Phase 2 N=37 A Study of TRS01 in Participants With Post-surgical Ocular Inflammation
Post Surgical Ocular Inflammation
Primary: Assessment of Both Systemic and Ocular Adverse Events — 0; 3; 0; 0 Number of TEAE
Phase 3 N=219 Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002b)
Inflammation
Primary: Anterior Chamber Cell Grade of "0" on Day 8 (Difluprednate QID vs Placebo). — 0; 18; 7 participants — p=<0.0001
Phase 3 N=380 Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation
Ocular Infections, Irritations and Inflammations
Primary: Resolution of Anterior Chamber Cells — 48; 39; 19 Participants — p=.0024
Phase 3 N=211 Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-1)
Cataract
Primary: Anterior Chamber Cell Grade — 67; 18 Participants
Phase 3 N=215 Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-2)
Cataract
Primary: Anterior Chamber Cell Grade — 38; 7 Participants
Phase 3 N=181 Study to Evaluate the Safety for the Treatment of Inflammation Associated With Cataract Surgery
Cataract
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 53; 13; 1; 0 Participants
Phase 3 N=241 OTX-14-003: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery
Post-Surgical Ocular Pain · Post-Surgical Ocular Inflammation
Primary: Number of Participants With an Absence of Anterior Chamber Inflammation — 63; 25 participants
Phase 4 N=94 No Drop Post-Op Cataract Surgery
Cataract
Primary: Best Corrected Visual Acuity (BCVA) (Pre-op) — .28 LogMar
Phase 3 N=311 Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Following Cataract Surgery
Cataract
Primary: Percentage of Participants With Complete Resolution of Anterior Chamber (AC) Cells. — 32; 12 Participants
Phase 3 N=438 OTX-15:003: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery
Post-Surgical Ocular Pain · Post-Surgical Ocular Inflammation
Primary: Absence of Anterior Chamber Inflammation — 52.3; 31.1 percentage of total participants
N/A N=50 Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery
Cataract · Retinal Edema · Inflammation
Primary: Treatment of Inflammation Associated With Cataract Surgery — 0.01; 0.01 units on a scale
Phase 2 N=60 Phase II Study Evaluating Safety/Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery
Ocular Inflammation and Pain
Primary: Absence of Cells in Anterior Chamber of Study Eye — 6; 3 Participants
Phase 3 N=369 Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
Cataract · Inflammation · Surgery
Primary: Percentage of Participants With Complete Resolution of Anterior Chamber (AC) Cells — 49; 15 Participants
Phase 3 N=178 Clinical Study of the Efficacy of the Ophthalmic Emulsion PRO-145 for Inflammation and Pain After Phacoemulsification
Cataract
Primary: Visual Ability (VA) — 0.91; 0.87 units on a scale (LogMAR) — p=0.065
Phase 3 N=514 Loteprednol Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
Inflammation · Pain · Cataract
Primary: Percentage of Participants With Complete Resolution of Anterior Chamber (AC) Cells — 16; 46; 49 Participants
Phase 3 N=247 Phase 3 Study Evaluating Safety and Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery
Post Ocular Surgical Inflammation and Pain
Primary: Absence of Cells in Anterior Chamber of the Study Eye — 54; 12 Participants
Phase 3 N=394 The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery
Inflammation · Cataracts
Primary: Number of Participants With Anterior Chamber Cell Clearing — 99; 103; 20 Participants
Phase 3 N=400 Loteprednol Etabonate Ophthalmic Ointment vs. Vehicle in the Treatment of Inflammation Following Cataract Surgery
Ocular Inflammation
Primary: Subjects With Complete Resolution of Anterior Chamber Cells and Flare. Grade=0. — 48; 27; 153; 172 participants
Phase 3 N=326 Loteprednol Etabonate Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
Inflammation · Pain · Cataract
Primary: Percentage of Participants With Complete Resolution of Anterior Chamber (AC) Cells — 38; 29 Participants
Phase 4 N=131 Loteprednol vs. Prednisolone and Fluorometholone
Intraocular Pressure · Corneal Opacity
Primary: Change in Intraocular Pressure (IOP) From Baseline Through Month 3 — 14.38; 14.30; 13.67; 13.28 mmHg
Phase 2 N=415 Evaluation of BOL-303242-X Versus Vehicle for the Treatment of Inflammation Following Cataract Surgery
Cataract · Inflammation
Primary: Percentage of Participants With Complete Resolution of Anterior Chamber (AC) Cells. — 35; 19; 15; 47 Participants
Phase 3 N=107 Loteprednol vs Prednisolone for the Treatment of Intraocular Inflammation Following Cataract Surgery in Children.
Cataract
Primary: Anterior Chamber Inflammation — .913; .783 grade of anterior chamber cells
Phase 3 N=405 Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery
Ocular Inflammation
Primary: Participants With Complete Resolution of Anterior Chamber Cells and Flare. Grade=0 — 64; 23 participants
Phase 3 N=241 A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Eyedrops Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
Inflammation Eye Pain · Postoperative Cataract
Primary: Absence of Anterior Chamber Cells at Visit 6. — 57.2; 24.0 percentage of study eyes — p=<0.0001
N/A N=49 Clinical Outcomes and Evaluation of Lotemax 0.5% in Treatment of Ocular Inflammation Associated With Cataract Surgery
Pseudophakia · Inflammation
Primary: Investigate Clinical Outcomes for Intraocular Pressure After Treatment With Lotemax (Loteprednol Ophthalmic Solution) 0.5% QID in Subjects Who Have Undergone Cataract…